How to reducecalcitonin gene-related peptide Calcitonin gene-related peptide (CGRP) medications represent a significant advancement in the management of migraine headaches, offering novel approaches for both prevention and acute treatment. These therapies target the calcitonin gene-related peptide pathway, a key player in migraine pathophysiology2016年2月3日—These drugs appear to be highly effective and specific medications designed to eitherprevent or acutely treat migraines through blocking the pain pathway.. Unlike older treatments that offered broader symptom relief, CGRP-targeted therapies are specifically designed to address the underlying mechanisms of migraine, marking a new frontier in neurological treatment.
Calcitonin gene-related peptide (CGRP) is a neuropeptide found throughout the nervous system, playing a role in various physiological processes, including vasodilation and pain transmission. Emerging research has strongly implicated CGRP in the development of migraines15 Frequently Asked Questions About CGRP Monoclonal Antibodies and .... During a migraine attack, elevated levels of CGRP are believed to contribute to the inflammation and dilation of blood vessels in the brain, leading to the characteristic throbbing pain. By inhibiting the action of CGRP or blocking its receptor, these new medications aim to disrupt this process and alleviate migraine symptoms.
The CGRP medications currently available fall into two primary categories: monoclonal antibodies and small molecule antagonists (gepants). Both classes work by interfering with the CGRP pathway, but they differ in their administration and specific targets.
1. CGRP Monoclonal Antibodies (mAbs)
These are injectable medications designed for migraine prevention. They work by binding to either the CGRP molecule itself or its receptor, effectively blocking CGRP's signaling.Calcitonin Gene-Related Peptide Inhibitors for Migraine Prevention ... Approved CGRP monoclonal antibodies include:
* Erenumab (Aimovig): Targets the CGRP receptor.
* Fremanezumab (Ajovy): Targets the CGRP molecule.
* Galcanezumab (Emgality): Targets the CGRP molecule.
* Eptinezumab (Vyepti): Targets the CGRP molecule and is administered intravenously.
These antibodies are typically administered monthly or quarterly, depending on the specific drug and dosage. They are primarily indicated for individuals who experience frequent migraines and have not found adequate relief from traditional preventive therapiesStrong evidence of the efficacy oftriptans, acetaminophen, aspirin, diclofenac sodium, naproxen and ibuprofenfor the acute treatment of migraines.. Clinical trials have demonstrated their efficacy in reducing migraine frequency and severity.
2. CGRP Receptor Antagonists (Gepants)
Gepants are a newer class of oral medications that act as small molecule antagonistsCGRP Inhibitors & Antagonist Drugs List. They work by blocking the CGRP receptor, preventing CGRP from binding to it and initiating its effects. Gepants can be used for both the acute treatment of migraine attacks and, in some cases, for preventionCalcitonin Gene-Related Peptide Receptor Antagonists.
* Rimegepant (Nurtec ODT): Approved for both acute treatment and prevention of episodic migraine2016年2月3日—These drugs appear to be highly effective and specific medications designed to eitherprevent or acutely treat migraines through blocking the pain pathway..
* Ubrogepant (Ubrelvy): Approved for the acute treatment of migraine.
* Atogepant (Qulipta): Approved for the preventive treatment of episodic migraine.
* Zavegepant: An intranasal gepant approved for acute migraine treatment.
The development of oral gepants offers a more convenient option for patients, particularly for acute treatment when an injection may not be practical.Gepants: Both A Preventive and An Acute Treatment for Migraine Their dual utility in both acute and preventive settings expands treatment possibilities for many migraine sufferers.
CGRP medications are generally considered for individuals with frequent migraines, including those with episodic or chronic migraine, who have not responded well to or cannot tolerate other migraine treatments.作者：M Li·2025·被引用次数：6—All 8 CGRP-targeted therapy drugs were not suitable for children.For elderly,erenumab, galcanezumab, ubrogepant, atogepant and zavegepant... This includes patients who have not found sufficient relief with conventional therapies such as triptans, acetaminophen, aspirin, diclofenac sodium, naproxen, and ibuprofen.Calcitonin gene-related peptide–targeted therapies for migraine The specific indication for each medication (acute treatment, prevention, or both) will guide its use by healthcare professionalsStrong evidence of the efficacy oftriptans, acetaminophen, aspirin, diclofenac sodium, naproxen and ibuprofenfor the acute treatment of migraines.. It is important for patients to discuss their migraine history and treatment goals with their doctor to determine if CGRP-targeted therapy is appropriate.
While CGRP medications have shown a favorable safety profile compared to some older migraine drugs, they can still cause side effects. Common side effects reported for monoclonal antibodies include injection site reactions, upper respiratory tract infections, and fatigue2024年11月5日—Common Triptans available in Australia include Sumatriptan (Imitrex, Imigran), Rizatriptan (Maxalt), Eletriptan (Relpax), Zolmitriptan (Zomig) .... For gepants, potential side effects may include nausea, fatigue, and dizziness.
It is crucial for patients to be aware that not all individuals respond to CGRP medications.Effectiveness of Anti-Calcitonin Gene-Related Peptide ... Some may experience significant relief, while others might see only modest improvements or no benefit at all. Additionally, long-term data on the use of these newer therapies is still accumulating.作者：H Scans—Evidence from phase III RCTs showed thatrimegepant and ubrogepantwere better than placebo for two key outcomes — freedom from pain and freedom ... It is essential for patients to undergo regular monitoring by their healthcare provider while on these medications to assess efficacy and manage any potential adverse effects. The suitability of these medications for specific populations, such as children or the elderly, is also an ongoing area of research, with some therapies showing specific limitations for certain age groups.
The development of CGRP-targeted therapies has revolutionized migraine management, moving beyond symptom suppression to address the underlying biological mechanisms of the condition. Ongoing research continues to explore new CGRP antagonists, delivery methods, and potential applications beyond migraine. As more data becomes available, the role of CGRP medications in neurological care is expected to expand, offering renewed hope for individuals living with the debilitating effects of migraine.
Join the newsletter to receive news, updates, new products and freebies in your inbox.